Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751017 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants
A Phase 1 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06751017 is a Phase 1 study that has completed, run by Shionogi. The registered enrollment target is 16 participants.
The verdict
NCT06751017, a Phase 1 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the effect of multiple-dose administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults.
Interventions
- DRUG Carbamazepine
- DRUG S-892216
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06751017
The ClinicalTrials.gov registry entry for NCT06751017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbamazepine is the first listed.
NCT06751017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06751017 about?
NCT06751017 is a clinical study titled "A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants". The primary objective of this study is to investigate the effect of multiple-dose administration of carbamazepine on the pharmacokinetics of S-892216 in healthy adults.
What is the current status of trial NCT06751017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-12-17. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT06751017?
The interventions under investigation include: Carbamazepine (DRUG), S-892216 (DRUG).
Who is sponsoring clinical trial NCT06751017?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.